In a groundbreaking move, Vividion Therapeutics and Bayer have joined forces to propel the development of VVD-214, the world’s pioneer clinical-stage covalent WRN inhibitor, targeting MSI-high cancers such as colorectal, endometrial, ovarian, and gastric tumors. The promise that this novel compound holds is truly monumental, particularly for patients whose conditions have proven resistant to immune […]